Literature DB >> 20013284

[Critical overview of outcome parameters for patients with primary Sjögren's syndrome].

E Feist1, A Hansen.   

Abstract

Not only in the context of clinical trials in particular, but also in daily clinical practice, outcome parameters or measuring instruments are essential to assess the efficacy of a therapeutic intervention, its influence on disease activity and potentially also to predict further disease course. Such criteria can assist in the identification of patient risk groups that may require special checkups or interventions. Moreover, these parameters should be reliable, objective and valid, e.g. to allow comparison of results from different studies. Therefore, outcome parameters need to be developed and/or validated in a targeted manner for individual diseases or investigations. To date, we have only limited therapeutic options for Sjögren's syndrome, a frequent systemic autoimmune disorder of unknown origin. Against the background of the new therapy approaches expected, this article provides a critical overview of available and newly developed outcome parameters for patients with Sjögren's syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20013284     DOI: 10.1007/s00393-009-0516-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

Review 1.  Sonography of the salivary glands.

Authors:  N Gritzmann; T Rettenbacher; A Hollerweger; P Macheiner; E Hübner
Journal:  Eur Radiol       Date:  2002-09-05       Impact factor: 5.315

Review 2.  Clinical manifestations and early diagnosis of Sjögren syndrome.

Authors:  Stuart S Kassan; Haralampos M Moutsopoulos
Journal:  Arch Intern Med       Date:  2004-06-28

Review 3.  Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA.

Authors:  Stanley R Pillemer; Janine Smith; Philip C Fox; Simon J Bowman
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

4.  Ultrasonographic changes of major salivary glands in primary Sjögren's syndrome. Evaluation of a novel scoring system.

Authors:  Alojzija Hocevar; Sasa Rainer; Blaz Rozman; Polonca Zor; Matija Tomsic
Journal:  Eur J Radiol       Date:  2007-03-06       Impact factor: 3.528

Review 5.  [Indications and options of new immune modulatory therapies for Sjögren's syndrome].

Authors:  E Feist; T Dörner; A Hansen
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

6.  Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

Authors:  Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

7.  Quantitative analyses of sonographic images of the parotid gland in patients with Sjögren's syndrome.

Authors:  Toru Chikui; Kazutoshi Okamura; Kenji Tokumori; Seiji Nakamura; Mayumi Shimizu; Makoto Koga; Kazunori Yoshiura
Journal:  Ultrasound Med Biol       Date:  2006-05       Impact factor: 2.998

8.  The Xerostomia Inventory: a multi-item approach to measuring dry mouth.

Authors:  W M Thomson; J M Chalmers; A J Spencer; S M Williams
Journal:  Community Dent Health       Date:  1999-03       Impact factor: 1.349

Review 9.  B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.

Authors:  Arne Hansen; Peter E Lipsky; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

10.  Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye.

Authors:  Susan Vitale; Linda A Goodman; George F Reed; Janine A Smith
Journal:  Health Qual Life Outcomes       Date:  2004-09-01       Impact factor: 3.186

View more
  1 in total

Review 1.  [Sjögren syndrome].

Authors:  A Hansen; T Dörner
Journal:  Internist (Berl)       Date:  2010-10       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.